신장병 치료제 시장 보고서(2026년)

Nephrology drugs, also referred to as renal drugs, are medications used in the management and treatment of kidney-related conditions. These drugs are often associated with the control of high blood pressure and hypertension and are used to improve kidney function, slow disease progression, and prevent further damage to the body.

The main types of drugs used in nephrology include antihypertensive agents, erythropoiesis-stimulating agents, diuretics, ACE inhibitors, antidiabetic agents, and others. Antihypertensive agents are a class of medications used to manage high blood pressure and act through various mechanisms to control hypertension. These drugs are administered through different routes such as oral, parenteral, and other methods, and are distributed via hospital pharmacies, online pharmacies, and retail pharmacies. The primary end users of nephrology drugs include hospitals, homecare settings, specialty clinics, and other healthcare providers.

Tariffs have impacted the nephrology drugs market by increasing the cost of imported raw materials, active pharmaceutical ingredients (APIs), and finished renal medications. This has led to higher production costs, particularly affecting antihypertensive agents, erythropoiesis-stimulating agents, and diuretics. Regions such as Asia-Pacific, where manufacturing and export hubs like China and India dominate, are most affected. However, tariffs have also encouraged local production and innovation, driving development of cost-effective renal drugs and alternative supply strategies

The nephrology drugs market research report is one of a series of new reports from The Business Research Company that provides nephrology drugs market statistics, including nephrology drugs industry global market size, regional shares, competitors with a nephrology drugs market share, detailed nephrology drugs market segments, market trends and opportunities, and any further data you may need to thrive in the nephrology drugs industry. This nephrology drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The nephrology drugs market size has grown strongly in recent years. It will grow from $17.69 billion in 2025 to $18.74 billion in 2026 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to early adoption of antihypertensive agents, increasing cases of chronic kidney disease, growing hospital infrastructure for renal care, advancements in dialysis and parenteral treatments, rising awareness of kidney-related disorders.

The nephrology drugs market size is expected to see strong growth in the next few years. It will grow to $24.32 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to development of precision medicine for nephrology, integration of ai in renal drug development, expansion of homecare treatment solutions, rising investment in biotechnology for kidney therapies, adoption of digital health monitoring for kidney patients. Major trends in the forecast period include personalized kidney care solutions, rising prevalence of hypertension-related kidney disorders, advancements in renal drug formulations, growing awareness of chronic kidney disease management, increased adoption of home-based renal treatments.

The increasing prevalence of chronic kidney disease is anticipated to drive the growth of the nephrology drugs market in the coming years. Chronic kidney disease (CKD) refers to a condition in which the kidneys are damaged and unable to filter blood as efficiently as they should, as the damage develops slowly over an extended period. As a result, waste materials can build up in the body. Nephrology drugs are mainly used to treat chronic kidney disease by improving kidney function and slowing disease progression, thereby preventing further damage to the body, and these factors are contributing to the expansion of the nephrology drugs market. For instance, in June 2023, according to Oxford Academic, a UK-based academic research platform of Oxford University Press, the prevalence of CKD in the UK is expected to increase by 4%, from 8.27 million to 8.61 million people between 2022 and 2032, with the stage distribution in 2032 projected to be 30.36% for stage 1, 21.07% for stage 2, 29.78% for stage 3a, 11.86% for stage 3b, 4.15% for stage 4, and 2.78% for stage 5. Therefore, the rising prevalence of chronic kidney disease is fueling the growth of the nephrology drugs market.

Leading companies operating in the nephrology drugs market are concentrating on obtaining approvals for innovative products, such as the U.S. Food and Drug Administration approval of Jardiance (empagliflozin), to better address the needs of their existing customers. Empagliflozin is a diabetic medication used to manage and treat type 2 diabetes mellitus and belongs to the sodium-glucose co-transporter (SGLT-2) class of diabetic drugs. It lowers blood sugar levels by promoting the excretion of excess glucose through the urine via the kidneys. For example, in January 2023, Eli Lilly and Company, a US-based pharmaceutical company, along with Boehringer Ingelheim, announced that the Food and Drug Administration approved a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) tablets, which are being studied as a potential treatment to reduce the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease (CKD). Boehringer Ingelheim is a pharmaceutical company based in Germany.

In January 2024, Novartis AG, a Switzerland-based pharmaceutical company, acquired SanReno Therapeutics for an undisclosed sum. This acquisition highlights Novartis' commitment to strengthening its presence in the renal market, particularly in Greater China and Singapore, where there is considerable growth potential for nephrology therapeutics. The strategic acquisition also supports Novartis' broader objective of advancing innovative treatments for kidney diseases and reinforcing its competitive position in the nephrology drugs market. SanReno Therapeutics is a China-based clinical-stage biotechnology company focused on developing innovative therapies for kidney diseases, especially Immunoglobulin A Nephropathy (IgAN).

Major companies operating in the nephrology drugs market are AstraZeneca plc, AbbVie Inc., Akebia Therapeutics Inc., Amgen Inc., FibroGen Inc., Johnson And Johnson, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Reata Pharmaceuticals Inc., Ardelyx Inc., Novo Nordisk A/S, Novartis AG, Baxter International Inc., Bristol Myers Squibb Company, Kissei Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Mallinckrodt Pharmaceuticals, OPKO Health Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Vifor Pharma Group, Bayer AG, Otsuka Pharmaceutical Co. Ltd., Mylan N.V.

North America was the largest region in the nephrology drug market in 2025. Europe will be the second-largest growing region in the nephrology drug market in 2025. The regions covered in the nephrology drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the nephrology drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nephrology drugs market consists of sales of invokana, phoslo, renvela, sensipar, and procrit drugs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nephrology Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses nephrology drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for nephrology drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The nephrology drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drugs: Antihypertensive Agents; Erythropoiesis-Stimulating Agents; Diuretics; ACE Inhibitors; Antidiabetic Agents; Other Drugs
• 2) By Route Of Administration: Oral; Parenteral; Other Route Of Administration
• 3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
• 4) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Antihypertensive Agents: Calcium Channel Blockers; Beta-Blockers; Angiotensin II Receptor Blockers (ARBs)
• 2) By Erythropoiesis-Stimulating Agents: Epoetin Alfa; Darbepoetin Alfa
• 3) By Diuretics: Loop Diuretics; Thiazide Diuretics; Potassium-Sparing Diuretics
• 4) By ACE Inhibitors: Lisinopril; Enalapril
• 5) By Antidiabetic Agents: Metformin; Insulin
• 6) By Other Drugs: Phosphate Binders; Vitamin D Analogues; Renin Inhibitors
• Companies Mentioned: AstraZeneca plc; AbbVie Inc.; Akebia Therapeutics Inc.; Amgen Inc.; FibroGen Inc.; Johnson And Johnson; Pfizer Inc.; GlaxoSmithKline plc; Teva Pharmaceutical Industries Limited; Boehringer Ingelheim International GmbH; Reata Pharmaceuticals Inc.; Ardelyx Inc.; Novo Nordisk A/S; Novartis AG; Baxter International Inc.; Bristol Myers Squibb Company; Kissei Pharmaceutical Co. Ltd.; Kyowa Kirin Co. Ltd.; Mallinckrodt Pharmaceuticals; OPKO Health Inc.; Sanofi S.A.; Takeda Pharmaceutical Company Limited; Vifor Pharma Group; Bayer AG; Otsuka Pharmaceutical Co. Ltd.; Mylan N.V.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Nephrology Drugs Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Nephrology Drugs Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Nephrology Drugs Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Nephrology Drugs Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Artificial Intelligence & Autonomous Intelligence
  • 4.1.2 Biotechnology, Genomics & Precision Medicine
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Sustainability, Climate Tech & Circular Economy
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Personalized Kidney Care Solutions
  • 4.2.2 Rising Prevalence Of Hypertension-Related Kidney Disorders
  • 4.2.3 Advancements In Renal Drug Formulations
  • 4.2.4 Growing Awareness Of Chronic Kidney Disease Management
  • 4.2.5 Increased Adoption Of Home-Based Renal Treatments

5. Nephrology Drugs Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Specialty Clinics
• 5.3 Homecare Providers
• 5.4 Renal Care Centers
• 5.5 Diagnostic Laboratories

6. Nephrology Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Nephrology Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Nephrology Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Nephrology Drugs Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Nephrology Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Nephrology Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Nephrology Drugs Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Nephrology Drugs Market Segmentation

• 9.1. Global Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Antihypertensive Agents, Erythropoiesis-Stimulating Agents, Diuretics, ACE Inhibitors, Antidiabetic Agents, Other Drugs
• 9.2. Global Nephrology Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Parenteral, Other Route Of Administration
• 9.3. Global Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
• 9.4. Global Nephrology Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Homecare, Specialty Clinics, Other End Users
• 9.5. Global Nephrology Drugs Market, Sub-Segmentation Of Antihypertensive Agents, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Calcium Channel Blockers, Beta-Blockers, Angiotensin II Receptor Blockers (ARBs)
• 9.6. Global Nephrology Drugs Market, Sub-Segmentation Of Erythropoiesis-Stimulating Agents, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Epoetin Alfa, Darbepoetin Alfa
• 9.7. Global Nephrology Drugs Market, Sub-Segmentation Of Diuretics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Loop Diuretics, Thiazide Diuretics, Potassium-Sparing Diuretics
• 9.8. Global Nephrology Drugs Market, Sub-Segmentation Of ACE Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Lisinopril, Enalapril
• 9.9. Global Nephrology Drugs Market, Sub-Segmentation Of Antidiabetic Agents, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Metformin, Insulin
• 9.10. Global Nephrology Drugs Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Phosphate Binders, Vitamin D Analogues, Renin Inhibitors

10. Nephrology Drugs Market Regional And Country Analysis

• 10.1. Global Nephrology Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Nephrology Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Nephrology Drugs Market

• 11.1. Asia-Pacific Nephrology Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Nephrology Drugs Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Nephrology Drugs Market

• 12.1. China Nephrology Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Nephrology Drugs Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Nephrology Drugs Market

• 13.1. India Nephrology Drugs Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Nephrology Drugs Market

• 14.1. Japan Nephrology Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Nephrology Drugs Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Nephrology Drugs Market

• 15.1. Australia Nephrology Drugs Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Nephrology Drugs Market

• 16.1. Indonesia Nephrology Drugs Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Nephrology Drugs Market

• 17.1. South Korea Nephrology Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Nephrology Drugs Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Nephrology Drugs Market

• 18.1. Taiwan Nephrology Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Nephrology Drugs Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Nephrology Drugs Market

• 19.1. South East Asia Nephrology Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Nephrology Drugs Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Nephrology Drugs Market

• 20.1. Western Europe Nephrology Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Nephrology Drugs Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Nephrology Drugs Market

• 21.1. UK Nephrology Drugs Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Nephrology Drugs Market

• 22.1. Germany Nephrology Drugs Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Nephrology Drugs Market

• 23.1. France Nephrology Drugs Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Nephrology Drugs Market

• 24.1. Italy Nephrology Drugs Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Nephrology Drugs Market

• 25.1. Spain Nephrology Drugs Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Nephrology Drugs Market

• 26.1. Eastern Europe Nephrology Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Nephrology Drugs Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Nephrology Drugs Market

• 27.1. Russia Nephrology Drugs Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Nephrology Drugs Market

• 28.1. North America Nephrology Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Nephrology Drugs Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Nephrology Drugs Market

• 29.1. USA Nephrology Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Nephrology Drugs Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Nephrology Drugs Market

• 30.1. Canada Nephrology Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Nephrology Drugs Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Nephrology Drugs Market

• 31.1. South America Nephrology Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Nephrology Drugs Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Nephrology Drugs Market

• 32.1. Brazil Nephrology Drugs Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Nephrology Drugs Market

• 33.1. Middle East Nephrology Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Nephrology Drugs Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Nephrology Drugs Market

• 34.1. Africa Nephrology Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Nephrology Drugs Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Nephrology Drugs Market Regulatory and Investment Landscape

36. Nephrology Drugs Market Competitive Landscape And Company Profiles

• 36.1. Nephrology Drugs Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Nephrology Drugs Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Nephrology Drugs Market Company Profiles
  • 36.3.1. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Akebia Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. FibroGen Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Nephrology Drugs Market Other Major And Innovative Companies

• Johnson And Johnson, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Reata Pharmaceuticals Inc., Ardelyx Inc., Novo Nordisk A/S, Novartis AG, Baxter International Inc., Bristol Myers Squibb Company, Kissei Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Mallinckrodt Pharmaceuticals, OPKO Health Inc.

38. Global Nephrology Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Nephrology Drugs Market

40. Nephrology Drugs Market High Potential Countries, Segments and Strategies

• 40.1 Nephrology Drugs Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Nephrology Drugs Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Nephrology Drugs Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer